4,539 Matching Annotations
  1. Nov 2021
    1. The combined use with fludarabine may lead to severe, even fatal, pulmonary toxicity.Fludarabine phosphate ([(2R,3R,4S,5R)-5-(6-amino-2-fluoro-purin-9-yl)-3,4-dihydroxy-oxolan-2-yl]methoxyphosphonic acid, 2-fluoro-ara-AMP) <Fludara, Oforta> is a fluorinated analog of vidarabine.Fludarabine phosphate is susceptible to glycosidic bond cleavage, which results in the formation of 2-fluoro-adenine, and is further converted to the highly toxic 2-fluoro-ATP.Fludarabine phosphate may be rapidly dephosphorylated by Phosphorylase cleavage to 2-fluoro-arabinosyladenine and then phosphorylated intracellularly by Deoxycytidine Kinase to the active triphosphate, 2-fluoro-arabinosyl-ATP.

      DCK phosphorylates triphosphoric acid.

    2. -This agent inhibits serine/threonine Protein Phosphatase type 2A (and to a lesser extent type 1) and Protein Phosphatase 4 (PP4), which leads to phosphorylation and reorganization of Vimentin filaments, thereby interfering with cellular proliferation.

      Phosphatase leads to the phosphorylation of VIM.

    3. At higher concentrations and longer exposure times, the slightly lipophilic agent clofarabine also enters cells by passive diffusion across lipid membranes.Clofarabine is phosphorylated by cytosolic kinases, including Deoxycytidine Kinase (DCK) and a Purine Nucleoside Monophosphate Kinase, to yield the active form clofarabine triphosphate.

      clofarabine phosphorylates DCK.

    4. The poly-glutamylation of anti-folates has been attempted to stabilize the compounds.Thymidylate Synthase inhibitors Thymidylate Synthase catalyzes the methylation of 2′-deoxyuridine-5′-monophosphate (dUMP) to 2′-deoxythymidine-5′monophosphate (dTMP), which is subsequently phosphorylated to thymidine triphosphate, an essential precursor in DNA synthesis (Fig. 2.42 ).

      dTMP phosphorylates dTTP.

    5. The poly-glutamylation of anti-folates has been attempted to stabilize the compounds.Thymidylate Synthase catalyzes the methylation of 2′-deoxyuridine-5′-monophosphate (dUMP) to 2′-deoxythymidine-5′-monophosphate (dTMP), which is subsequently phosphorylated to thymidine triphosphate, an essential precursor in DNA synthesis (Fig. 2.42).

      dTMP phosphorylates dTTP.

    6. This may reflect altered condensation with pyrophosphorylribose-5-phosphate (PRPP) or activation via the salvage pathway that involves ribose-1-phosphate or deoxyribose-1-phosphate and the appropriate Nucleoside Phosphorylase, with subsequent phosphorylation of the resultant nucleoside by Uridine Kinase or Thymidine Kinase.

      uridine phosphorylates nucleoside.

    7. 6-Mercaptopurine is inactivated via two major pathways,thiol methylation is catalyzed by the highly polymorphic enzyme Thiopurine S-Methyltransferase (TPMT), to form methyl-6-mercaptopurine.oxidation is catalyzed by Xanthine Oxidase and forms 6-thiouric acid.The metabolic products are rapidly eliminated by the kidneys, with close to 50 % of the administered dose being excreted in the first 24 h.Bone marrow depression is the main toxic effect.

      Thiopurine S-Methyltransferase (TPMT) leads to the methylation of thiol.

    8. Liposomal daunorubicin is under investigation for the treatment of AIDSrelated Kaposi sarcoma, acute myeloblastic leukemia, multiple myeloma, non-Hodgkin lymphoma, and breast cancer.Pharmacokinetics Carbonyl Reductase (CBR) catalyzes the reduction of daunorubicin to its corresponding alcohol, daunorubicinol, which changes the pharmacological properties of this cancer chemotherapeutic drug.

      CBR1 inhibits ethanol.

    9. The mean terminal elimination half-life of the active metabolite SN-38 is 10–20 h. SN-38 is inactivated via glucuronidation by UGT1A1 (Uridine Diphosphate Glucoronosyltransferase 1A1) into the non-toxic SN-38-glucuronide (SN-38G) and is excreted into the gastrointestinal tract.The most substantial adverse effects of irinotecan are grade 2 or higher nausea and vomiting, alopecia, asthenia, fever, and abdominal pain.

      UGT1A1 inhibits SN-38.

    10. The mean terminal elimination half-life of the active metabolite SN-38 is 10-20 h. SN-38 is inactivated via glucuronidation by UGT1A1 (Uridine Diphosphate Glucoronosyltransferase 1A1) into the non-toxic SN-38-glucuronide (SN-38G) and is excreted into the gastrointestinal tract.Adverse Effects The most substantial adverse effects of irinotecan are grade 2 or higher nausea and vomiting, alopecia, asthenia, fever, and abdominal pain.

      UGT1A1 inhibits SN-38.

    11. Thymidylate Synthase inhibitors Thymidylate Synthase catalyzes the methylation of 2 ' - deoxyuridine-5 ' - monophosphate ( dUMP ) to 2 ' - deoxythymidine-5'monophosphate ( dTMP ) , which is subsequently phosphorylated to thymidine triphosphate , an essential precursor in DNA synthesis ( Fig. 2.42 ) .

      TYMS inhibits methylation.

    12. blocked, comprising the synthesis of tetrahydrofolate ( THF), 1-carbon donors (1 C donors), and the production of essential molecules for cell proliferation regulatory elements are associated with clinical outcome in the treatment of osteosarcoma or childhood acute lymphoblastic leukemia (ALL).

      BCR inhibits oxolane.

    13. They share a polycyclic aromatic core structure.The 2 main modes of anthracycline action comprise Topoisomerase inhibition and generation of reactive oxygen species.Because first generation anthracyclines are associated with myocardial dysfunction and alopecia, second generation drugs attempt to reduce these adverse effects.Because of enhanced total body clearance, epirubicin can be used at high cumulative doses without increased cardiotoxicity.Oligosaccharide anthracyclines induce hematopoietic differentiation.The diaminoalkyl groups are crucial for the biological activity of anthracenediones.

      TOP inhibits dioxygen.

    14. Platelet counts may drop.Drug Resistance Treatment with verapamil may reduce resistance to tallimustine.MEN 10710 is a synthetic distamycin derivative that possesses four methyl-pyrrole rings and a bis-(2-chloroethyl) aminophenyl moiety linked to the oligopyrrole backbone by a flexible butanamido chain.Brostallicin (PNU-166196) is a bromo-acrylamido tetrapyrrole distamycin derivative with high cytotoxic potency.

      verapamil inhibits tetrapyrrole.

    15. The agent can be effectively combined with other nucleoside analogs, particularly clofarabine and gemcitabine, which inhibit Ribonucleotide Reductase.Other pyrimidine antagonists Penclomedine (3,5-dichloro -2,4-dimethoxy-6 trichloromethyl pyridine) (NSC338720) is a synthetic derivative of pyrimidine that alkylates and crosslinks DNA, resulting in DNA strand breaks and inhibition of DNA and RNA synthesis.

      clofarabine inhibits ribonucleotide.

    16. The agent can be effectively combined with other nucleoside analogs, particularly clofarabine and gemcitabine, which inhibit Ribonucleotide Reductase.Other pyrimidine antagonists Penclomedine (3,5-dichloro -2,4-dimethoxy-6 trichloromethyl pyridine) (NSC338720) is a synthetic derivative of pyrimidine that alkylates and crosslinks DNA, resulting in DNA strand breaks and inhibition of DNA and RNA synthesis.

      clofarabine inhibits pyrimidine.

    17. Drug Resistance The clinical use of anthracycline antibiotics is hampered by the development of resistance in tumor cells, which may be due to an over-expression of ABCB1 (MDR1, PGP), increased levels of enzymes that protect form reactive oxygen damage, activation of the transcription factor NF-κB that exerts crucial functions in cellular resistance to oxidants, altered topoisomerase 2 gene expression or activity, or enzymatic drug inactivation.The anthracycline daunorubicin was originally isolated from bacteria in soil samples taken from the Italian castle Castel del Monte.

      anthracycline inhibits drug.

    18. Because aminosalicylate derivatives may inhibit the enzyme Thiopurine S-Methyltransferase (TPMT) they should be administered with caution to patients on 6-mercaptopurine therapy.The mercaptopurine derivative methylthioinosine (6-(methylmercapto)purine riboside, 6-MMPR) inhibits Amidophosphoribosyl Transferase, the first committed step in de novo purine synthesis, and inhibits cell proliferation induced by Fibroblast Growth Factor-2 (FGF-2).

      6-methylthioinosine inhibits Transferases.

    19. Because aminosalicylate derivatives may inhibit the enzyme Thiopurine S-Methyltransferase (TPMT) they should be administered with caution to patients on 6-mercaptopurine therapy.The mercaptopurine derivative methylthioinosine (6-(methylmercapto)purine riboside, 6-MMPR) inhibits Amidophosphoribosyl Transferase, the first committed step in de novo purine synthesis, and inhibits cell proliferation induced by Fibroblast Growth Factor-2 (FGF-2).

      6-methylthioinosine inhibits cell population proliferation.

    20. A ratio of clofarabine triphosphate to dATP < 1 results in the insertion of clofarabine monophosphate into the middle of the DNA structure and inhibits DNA repair.Clofarabine triphosphate inhibits Ribonucleotide Reductase, leading to a depletion of the deoxyribonucleotide triphosphate (dNTP) pools.Clofarabine induces apoptosis through direct and indirect action on mitochondria by releasing Cytochrome c and other pro-apoptotic factors, including AIF (Apoptosis Inducing Factor), APAF-1 (Apoptotic Protease Activating Factor-1), and Caspase-9.The agent received accelerated approval from the U.S. FDA in 2004.

      triphosphoric acid inhibits CYCS.

    21. A ratio of clofarabine triphosphate to dATP < 1 results in the insertion of clofarabine monophosphate into the middle of the DNA structure and inhibits DNA repair.Clofarabine triphosphate inhibits Ribonucleotide Reductase, leading to a depletion of the deoxyribonucleotide triphosphate (dNTP) pools.Clofarabine induces apoptosis through direct and indirect action on mitochondria by releasing Cytochrome c and other pro-apoptotic factors, including AIF (Apoptosis Inducing Factor), APAF-1 (Apoptotic Protease Activating Factor-1), and Caspase-9.The agent received accelerated approval from the U.S. FDA in 2004.

      triphosphoric acid inhibits apoptotic process.

    22. Hence the drug efficacy can potentially be enhanced by Helicase inhibitors.Illudins and acylfulvenes alkylate DNA, inhibit DNA synthesis, and deplete thiol anti-oxidant defenses.In 1965, cisplatin was discovered by Barnett Rosenberg, who explored the effects of electric fields on the growth of Escherichia coli bacteria (Rosenberg 1965) .

      cisplatin inhibits thiol.

    23. Camptothecin also inhibits RNA synthesis.Irinotecan is an S phase specific agent.Camptothecins exist in a pH dependent equilibrium between their active lactone and inactive ring-opened conformations.The stability of the lactone ring at physiological pH is a determinant of activity for all camptothecin analogs.Topotecan and irinotecan are substrates for the efflux pump ABCB1.

      camptothecin inhibits S phase.

    24. Thus, the effects of inosine dialdehyde are different from those caused by typical inhibitors of Ribonucleotide Reductase, which rapidly suppress DNA synthesis and cause arrest of the cells in G 1 , with minimal effects on RNA and protein synthesis.In salvage pathways, nucleotides are synthesized from intermediates of canonical degradative pathways.

      ribonucleotide inhibits G1 phase.

    25. Nausea, vomiting, diarrhea, and an elevation of hepatic enzymes and bilirubin occur less often.Trimetrexate glucuronate (TMQ, 2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)methyl] quinazoline mono-D-glucuronate) <Neutrexin> is a lipid soluble methotrexate derivative that inhibits Dihydrofolate Reductase.

      glucuronate inhibits DHFR.

    26. Unlike methotrexate, edatrexate has additive activity when used with cisplatin.Talotrexin ammonium (N(α )-(4-amino-4-deoxypteroyl)- N(δ)-hemiphthaloyl-L-ornithine) (PT523) <Talvesta> is a non-polyglutamable anti-metabolite analog of aminopterin that binds to and inhibits the function of Dihydrofolate Reductase.

      4-aminofolic acid inhibits DHFR.

    27. Its cytotoxicity is not affected by disruption of P53 function or loss of DNA repair.In the presence of divalent cations, aureolic acid antibiotics form dimers that non-intercalatively bind to the DNA minor groove in high-GC-content regions.Upon binding to DNA, the aureolic acid chromophores form hydrogen bonds with NH2 residues of guanines.Mithramycin A binds to C/G-rich tracts as a dimer and blocks SP-1 family transcription factors.Ecteinascidin-743 effects guanine N2 alkylation.After intravenous administration, mitomycin C is rapidly cleared from the blood with a half-life of about 15 min.

      dihydrogen inhibits transcription, DNA-templated.

    28. The agent can be effectively combined with other nucleoside analogs, particularly clofarabine and gemcitabine, which inhibit Ribonucleotide Reductase.Other pyrimidine antagonists Penclomedine (3,5-dichloro -2,4-dimethoxy-6 trichloromethyl pyridine) (NSC338720) is a synthetic derivative of pyrimidine that alkylates and crosslinks DNA, resulting in DNA strand breaks and inhibition of DNA and RNA synthesis.

      gemcitabine inhibits ribonucleotide.

    29. The agent can be effectively combined with other nucleoside analogs, particularly clofarabine and gemcitabine, which inhibit Ribonucleotide Reductase.Penclomedine (3,5-dichloro-2,4-dimethoxy-6 trichloromethyl pyridine) (NSC338720) is a synthetic derivative of pyrimidine that alkylates and cross-links DNA, resulting in DNA strand breaks and inhibition of DNA and RNA synthesis.

      gemcitabine inhibits pyrimidine.

    30. The agent can be effectively combined with other nucleoside analogs, particularly clofarabine and gemcitabine, which inhibit Ribonucleotide Reductase.Other pyrimidine antagonists Penclomedine (3,5-dichloro -2,4-dimethoxy-6 trichloromethyl pyridine) (NSC338720) is a synthetic derivative of pyrimidine that alkylates and crosslinks DNA, resulting in DNA strand breaks and inhibition of DNA and RNA synthesis.

      gemcitabine inhibits pyrimidine.

    31. Because of its higher concentration in the combination, uracil saturates the uracil reducing enzymatic activity of Ddihydropyrimidine Ddehydrogenase, thereby inhibiting first pass hepatic metabolism of 5-fluorouracil and permitting its administration as the orally bioavailable prodrug tetrahydrofuranyl-5-fluorouracil.

      uracil inhibits 5-fluorouracil.

    32. The agent can be effectively combined with other nucleoside analogs, particularly clofarabine and gemcitabine, which inhibit Ribonucleotide Reductase.Other pyrimidine antagonists Penclomedine (3,5-dichloro -2,4-dimethoxy-6 trichloromethyl pyridine) (NSC338720) is a synthetic derivative of pyrimidine that alkylates and crosslinks DNA, resulting in DNA strand breaks and inhibition of DNA and RNA synthesis.

      pyrimidine inhibits ribonucleotide.

    33. Their activation occurs with the release of the single-bonded nitrogen, leaving the highly reactive double-bonded diazonium fragment exposed.Oral availability and penetration of the blood-brain barrier vary among triazenes.The bis(sulfonyl)hydrazines are alkylating agents that produce chloroethylating species.Methyl benzyl hydrazine derivatives can suppress mitosis by prolonging interphase.Because absorption from the gastrointestinal tract is variable, thioTEPA should not be administered orally.

      hydrazine inhibits mitotic cell cycle.

    34. Hence the drug efficacy can potentially be enhanced by Helicase inhibitors.Illudins and acylfulvenes alkylate DNA, inhibit DNA synthesis, and deplete thiol anti-oxidant defenses.In 1965, cisplatin was discovered by Barnett Rosenberg, who explored the effects of electric fields on the growth of Escherichia coli bacteria (Rosenberg 1965) .

      Helicase inhibits drug.

    35. After uptake, it is O-demethylated by Adenosine Deaminase to ara-G, mono-phosphorylated by Deoxyguanosine Kinase and Deoxycytidine Kinase, and subsequently converted to the biologically active 9-β-D-arabinosylguanine 5′-triphosphate (ara-GTP).

      ADA demethylates araG.

    36. It displays an acceptable safety profile.Sensitive tumor cells convert the prodrug 6-mercaptopurine to thioinosinate and 6-methylthioinosinate, which inhibit Glutamine-5-Phosphoribosylpyrophosphate Amidotransferase, the first enzyme unique to the de novo synthesis pathway for purine ribonucleotides.The Adenosine Deaminase (ADA) inhibitor co-vidarabine is effective against several lymphoproliferative conditions, but not acute lymphocytic leukemia because the transformed cells contain too high levels of Adenosine Deaminase.After uptake, nelarabine is O-demethylated by Adenosine Deaminase to ara-G, mono-phosphorylated by Deoxyguanosine Kinase and Deoxycytidine Kinase, and subsequently converted to the biologically active 9-β-D-arabinosylguanine 5′-triphosphate (ara-GTP).

      ADA demethylates araG.

    37. Estramustine and its major metabolite bind covalently to microtubule-associated proteins (MAPs) and Tubulin, thereby causing their separation from the microtubules, inhibiting microtubule assembly, and eventually causing their disassembly.Estramustine is taken orally, at least 1 h before or 2 h after meals.

      estramustine binds Tubulin.

    38. Functional groups that differ from the parent compound, daunorubicin, are highlighted in pink cline and HCHO then react to form a conjugate, in which two anthracycline molecules bind together with three methylene groups, two forming oxazolidine rings and one binding the oxazolidines together at their 3′-amino nitrogens.

      oxazolidines binds oxazolidine.

    39. It depends on binding of a bleomycin/iron complex to DNA, which then reduces molecular oxygen to free oxygen radicals that cause primarily single strand breaks.Bleomycin sulfate <Blenoxane, Teva> is used in the treatment of Hodgkin and non-Hodgkin lymphoma as a component of the ABVD (adriamycin, bleomycin, vinblastine, dacarbazine) regimen, of squamous cell carcinoma, and of testicular cancer.

      iron atom binds bleomycin.

    40. Major binding interactions between the apoprotein and the chromophore are the hydrophobic contacts between the core of the chromophore and the hydrophobic side chains of the pocket forming residues.Neocarzinostatin (zinostatin, vinostatin), discovered in 1964, was the first enediyne antibiotic used clinically and has become a prototypical anti-cancer agent for the treatments of leukemia, gastric carcinoma and pancreatic adenocarcinoma.

      apoprotein binds chromophore.

    41. Other adverse effects include mild nausea and vomiting during treatment, bone marrow hypoplasia, nephrosis, emesis, and bloody diarrhea.Prior treatment with a nitrosourea enhances the hematopoietic toxicity of indicine-N-oxide.Dianhydrogalactitol (1,2:5,6-diepoxyhexane-3,4-diol, 1,2-di(oxiranyl)ethylene glycol, dulcitol diepoxide, DAG) (NSC 132313) is a bifunctional hexitol diepoxide that was developed in Budapest (Nemeth et al. 1972).

      Nausea activates hexitol.

    42. It is secreted in the milk.Irinotecan can induce both early and late forms of diarrhea, which may be severe.Early diarrhea can be accompanied by cholinergic symptoms of rhinitis, increased salivation, miosis, lacrimation, diaphoresis, flushing, and intestinal hyperperistalsis that can cause abdominal cramping.

      Diarrhea activates Miosis.

    43. It is secreted in the milk.Irinotecan can induce both early and late forms of diarrhea, which may be severe.Early diarrhea can be accompanied by cholinergic symptoms of rhinitis, increased salivation, miosis, lacrimation, diaphoresis, flushing, and intestinal hyperperistalsis that can cause abdominal cramping.

      Diarrhea activates Flushing.

    44. It depends on binding of a bleomycin/iron complex to DNA, which then reduces molecular oxygen to free oxygen radicals that cause primarily single strand breaks.Bleomycin sulfate <Blenoxane, Teva> is used in the treatment of Hodgkin and non-Hodgkin lymphoma as a component of the ABVD (adriamycin, bleomycin, vinblastine, dacarbazine) regimen, of squamous cell carcinoma, and of testicular cancer.

      Carcinoma, Squamous Cell activates sulfate.

    45. A ratio of clofarabine triphosphate to dATP < 1 results in the insertion of clofarabine monophosphate into the middle of the DNA structure and inhibits DNA repair.Clofarabine triphosphate inhibits Ribonucleotide Reductase, leading to a depletion of the deoxyribonucleotide triphosphate (dNTP) pools.Clofarabine induces apoptosis through direct and indirect action on mitochondria by releasing Cytochrome c and other pro-apoptotic factors, including AIF (Apoptosis Inducing Factor), APAF-1 (Apoptotic Protease Activating Factor-1), and Caspase-9.The agent received accelerated approval from the U.S. FDA in 2004.

      APAF1 activates CYCS.

    46. A ratio of clofarabine triphosphate to dATP < 1 results in the insertion of clofarabine monophosphate into the middle of the DNA structure and inhibits DNA repair.Clofarabine triphosphate inhibits Ribonucleotide Reductase, leading to a depletion of the deoxyribonucleotide triphosphate (dNTP) pools.Clofarabine induces apoptosis through direct and indirect action on mitochondria by releasing Cytochrome c and other pro-apoptotic factors, including AIF (Apoptosis Inducing Factor), APAF-1 (Apoptotic Protease Activating Factor-1), and Caspase-9.The agent received accelerated approval from the U.S. FDA in 2004.

      APAF1 activates apoptotic process.

    47. Because aminosalicylate derivatives may inhibit the enzyme Thiopurine S-Methyltransferase (TPMT) they should be administered with caution to patients on 6-mercaptopurine therapy.The mercaptopurine derivative methylthioinosine (6-(methylmercapto)purine riboside, 6-MMPR) inhibits Amidophosphoribosyl Transferase, the first committed step in de novo purine synthesis, and inhibits cell proliferation induced by Fibroblast Growth Factor-2 (FGF-2).

      FGF2 activates cell population proliferation.